- Home
- HCKT vs CHRS Comparison
HCKT vs CHRS Comparison
Compare HCKT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCKT | CHRS |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 296.8M |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HCKT | CHRS |
|---|---|---|
| Price | $10.16 | $1.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.00 | $5.51 |
| AVG Volume (30 Days) | 408.6K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $285,862,000.00 | N/A |
| Revenue This Year | $2.55 | $73.08 |
| Revenue Next Year | $5.07 | $30.94 |
| P/E Ratio | $58.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.16 | $0.72 |
| 52 Week High | $25.97 | $2.62 |
Technical Indicators
Market Signals| Indicator | HCKT | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 39.93 |
| Support Level | $9.16 | $1.21 |
| Resistance Level | $14.49 | $1.80 |
| Average True Range (ATR) | 0.70 | 0.11 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 21.87 | 11.63 |
Price Performance
Historical ComparisonAbout HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.